291 related articles for article (PubMed ID: 27757559)
1. 5T4 oncofoetal antigen: an attractive target for immune intervention in cancer.
Stern PL; Harrop R
Cancer Immunol Immunother; 2017 Apr; 66(4):415-426. PubMed ID: 27757559
[TBL] [Abstract][Full Text] [Related]
2. Understanding and exploiting 5T4 oncofoetal glycoprotein expression.
Stern PL; Brazzatti J; Sawan S; McGinn OJ
Semin Cancer Biol; 2014 Dec; 29():13-20. PubMed ID: 25066861
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer.
Woods AM; Wang WW; Shaw DM; Ward CM; Carroll MW; Rees BR; Stern PL
Biochem J; 2002 Aug; 366(Pt 1):353-65. PubMed ID: 12003637
[TBL] [Abstract][Full Text] [Related]
4. 5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.
Cappuccini F; Pollock E; Stribbling S; Hill AVS; Redchenko I
Oncotarget; 2017 Jul; 8(29):47474-47489. PubMed ID: 28537896
[TBL] [Abstract][Full Text] [Related]
5. Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy.
Griffiths RW; Gilham DE; Dangoor A; Ramani V; Clarke NW; Stern PL; Hawkins RE
Br J Cancer; 2005 Sep; 93(6):670-7. PubMed ID: 16222313
[TBL] [Abstract][Full Text] [Related]
6. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen.
Forsberg G; Ohlsson L; Brodin T; Björk P; Lando PA; Shaw D; Stern PL; Dohlsten M
Br J Cancer; 2001 Jul; 85(1):129-36. PubMed ID: 11437414
[TBL] [Abstract][Full Text] [Related]
7. CXCL12 receptor preference, signal transduction, biological response and the expression of 5T4 oncofoetal glycoprotein.
McGinn OJ; Marinov G; Sawan S; Stern PL
J Cell Sci; 2012 Nov; 125(Pt 22):5467-78. PubMed ID: 22956548
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy success in prophylaxis cannot predict therapy: prime-boost vaccination against the 5T4 oncofoetal antigen.
Ali S; Mulryan K; Taher T; Stern PL
Cancer Immunol Immunother; 2007 Feb; 56(2):165-80. PubMed ID: 16758205
[TBL] [Abstract][Full Text] [Related]
9. 5T4 oncotrophoblast glycoprotein: janus molecule in life and a novel potential target against tumors.
Zhao Y; Wang Y
Cell Mol Immunol; 2007 Apr; 4(2):99-104. PubMed ID: 17484803
[TBL] [Abstract][Full Text] [Related]
10. Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma.
Xu Y; Morales AJ; Cargill MJ; Towlerton AMH; Coffey DG; Warren EH; Tykodi SS
Cancer Immunol Immunother; 2019 Dec; 68(12):1979-1993. PubMed ID: 31686124
[TBL] [Abstract][Full Text] [Related]
11. Isolation of a high affinity scFv from a monoclonal antibody recognising the oncofoetal antigen 5T4.
Shaw DM; Embleton MJ; Westwater C; Ryan MG; Myers KA; Kingsman SM; Carroll MW; Stern PL
Biochim Biophys Acta; 2000 Dec; 1524(2-3):238-46. PubMed ID: 11113573
[TBL] [Abstract][Full Text] [Related]
12. Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy.
Castro FV; Al-Muftah M; Mulryan K; Jiang HR; Drijfhout JW; Ali S; Rutkowski AJ; Kalaitsidou M; Gilham DE; Stern PL
Cancer Immunol Immunother; 2012 Jul; 61(7):1005-18. PubMed ID: 22127365
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R
J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915
[TBL] [Abstract][Full Text] [Related]
14. The pattern of expression of the 5T4 oncofoetal antigen on normal, dysplastic and malignant oral mucosa.
Ali A; Langdon J; Stern P; Partridge M
Oral Oncol; 2001 Jan; 37(1):57-64. PubMed ID: 11120484
[TBL] [Abstract][Full Text] [Related]
15. Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma.
Al-Taei S; Salimu J; Lester JF; Linnane S; Goonewardena M; Harrop R; Mason MD; Tabi Z
Lung Cancer; 2012 Aug; 77(2):312-8. PubMed ID: 22498111
[TBL] [Abstract][Full Text] [Related]
16. 5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells.
Guo X; Zheng H; Luo W; Zhang Q; Liu J; Yao K
Sci Rep; 2017 Jul; 7(1):4859. PubMed ID: 28687750
[TBL] [Abstract][Full Text] [Related]
17. CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells.
Southgate TD; McGinn OJ; Castro FV; Rutkowski AJ; Al-Muftah M; Marinov G; Smethurst GJ; Shaw D; Ward CM; Miller CJ; Stern PL
PLoS One; 2010 Apr; 5(4):e9982. PubMed ID: 20376365
[TBL] [Abstract][Full Text] [Related]
18. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.
Amato RJ
Expert Opin Biol Ther; 2010 Feb; 10(2):281-7. PubMed ID: 20088718
[TBL] [Abstract][Full Text] [Related]
19. Metastasis-associated 5T4 oncofoetal antigen is concentrated at microvillus projections of the plasma membrane.
Carsberg CJ; Myers KA; Evans GS; Allen TD; Stern PL
J Cell Sci; 1995 Aug; 108 ( Pt 8)():2905-16. PubMed ID: 7593330
[TBL] [Abstract][Full Text] [Related]
20. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors.
Mulryan K; Ryan MG; Myers KA; Shaw D; Wang W; Kingsman SM; Stern PL; Carroll MW
Mol Cancer Ther; 2002 Oct; 1(12):1129-37. PubMed ID: 12481437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
